P2Y11 Antagonist NF 340: Applied Workflows in Cancer & Immunology

Principle Overview: Targeting P2Y11 for Translational Research

The P2Y11 receptor, a member of the purinergic G protein-coupled receptor (GPCR) family, orchestrates a spectrum of cellular responses central to inflammation and immune modulation. NF 340—a research-grade, highly selective P2Y11 antagonist (sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate)—serves as a powerful tool for interrogating this signaling axis (product_spec). By inhibiting P2Y11, NF 340 enables researchers to dissect the downstream effects of purinergic signaling in disease models, particularly in the context of breast cancer invasiveness and immune response regulation. Its application extends across cell-based assays, inflammation pathway studies, and advanced models of cancer cell migration (workflow_recommendation).

Step-by-Step Workflow: Integrating NF 340 into Experimental Design

Successful implementation of NF 340 in laboratory workflows demands attention to compound handling, assay integration, and endpoint selection. The following protocol outlines a robust approach for using NF 340 as a selective P2Y11 antagonist in breast cancer and immunology research, with parameters optimized for reproducibility and translational impact:

Protocol Parameters

• Assay: Cell migration/invasion (e.g., Transwell, wound healing) | NF 340 concentration: 5–10 μM | Breast cancer and immune cell lines | Achieves effective P2Y11 inhibition with minimal cytotoxicity | paper
• Vehicle: DMSO (0.1% final concentration) | Solubilization prior to aqueous dilution | Enhances solubility and stability for immediate use | product_spec
• Incubation: 24–48 hours with NF 340 | Allows for sufficient signaling modulation and endpoint measurement | Standard for migration/invasion readouts | paper
• Storage: -20°C (dry solid) | Protects compound integrity, avoid repeated freeze-thaw | Ensures consistent potency across experiments | product_spec
• Solution stability: Use immediately after preparation (do not store in solution) | Prevents hydrolysis and potency loss | Critical for reproducibility | workflow_recommendation

Key Innovation from the Reference Study

The pivotal study by Liu et al. (paper) established that NF 340 reverses breast cancer cell invasiveness driven by quinolinate phosphoribosyltransferase (QPRT) overexpression. By inhibiting P2Y11, NF 340 suppresses downstream phosphorylation of myosin light chain, thereby mitigating cytoskeletal remodeling and invasive potential. This mechanistic link not only confirms the role of P2Y11 in cancer cell motility but also provides a blueprint for using NF 340 in functional assays targeting purinergic signaling. For practical assay design, this translates into:

• Prioritizing cell migration or invasion endpoints as sensitive readouts of P2Y11 pathway modulation.
• Benchmarking NF 340 against other pathway inhibitors (e.g., Rho, ROCK, PLC inhibitors) to dissect signaling specificity.

Researchers can thus tailor their experimental approach to quantitatively assess the contribution of P2Y11 to cancer invasiveness and immune modulation, using NF 340 as a selective probe.

Advanced Applications and Comparative Advantages

NF 340’s high selectivity for the P2Y11 receptor sets it apart from broader-spectrum purinergic inhibitors, enabling precise dissection of GPCR signaling pathways in complex disease models. In immunology research, NF 340 has facilitated the analysis of inflammation pathway modulation by uncoupling P2Y receptor signaling from overlapping purinergic effects (complement). Compared to less selective compounds, NF 340 minimizes off-target effects, yielding cleaner interpretation of immune cell functional assays and cytokine profiling.

In oncology, the ability of NF 340 to reverse QPRT-induced cell migration and invasion supports its use in advanced models of cancer progression, including patient-derived xenografts and 3D co-culture systems (extension). Its compatibility with multiplexed readouts and pathway inhibitors (e.g., Y16, Y27632, U73122, ML7) further amplifies its value in mechanistic studies and pharmacological screens (contrast).

NF 340 is supplied by APExBIO as a beige solid with a molecular weight of 986.84 and a chemical formula of C₃₇H₂₆N₄Na₄O₁₅S₄. Its solubility in water is less than 19.74 mg/ml (product_spec), necessitating DMSO-based preparation for most protocols.

Troubleshooting and Optimization Tips

• Low compound solubility: Dissolve NF 340 first in DMSO at a high stock concentration (e.g., 10–20 mM), then dilute into cell culture medium to the desired final concentration, ensuring the DMSO percentage remains below 0.1% to avoid cytotoxicity (product_spec).
• Variable inhibition efficacy: Confirm cell line P2Y11 expression via RT-qPCR or immunoblotting prior to treatment. Use positive controls (e.g., known pathway inhibitors) and titrate NF 340 to find optimal blocking concentrations for your model (paper).
• Compound degradation: Prepare fresh working solutions immediately before use; do not store diluted NF 340 for extended periods, as hydrolysis may reduce activity (workflow_recommendation).
• Off-target effects: Include vehicle and unrelated GPCR antagonist controls to distinguish P2Y11-specific responses, especially in multiplexed or high-throughput screens (workflow_recommendation).
• Readout inconsistency: Standardize incubation times and endpoint assays (e.g., 24–48 hours for migration/invasion) to minimize variability (paper).

Product Access and Resource Integration

For detailed product information, handling precautions, and bulk ordering, visit the official NF 340 page at APExBIO. Researchers leveraging APExBIO’s validated supply chain benefit from batch-to-batch consistency, technical support, and integration with high-throughput screening platforms, as highlighted in recent workflow analyses (workflow_recommendation).

Why this Cross-Domain Matters, Maturity, and Limitations

The translational bridge between immunology and oncology established by NF 340 arises from the shared reliance on P2Y11-mediated purinergic signaling in both immune modulation and cancer cell invasion. This convergence enables the use of NF 340 as a universal probe in studies ranging from inflammation pathway mapping to metastatic potential assessment. While preclinical validation is robust, especially in breast cancer and immune models, use in other domains (e.g., cardiovascular or antiviral research) should be approached cautiously unless supported by additional mechanistic data (workflow_recommendation).

Future Outlook: Implications and Next Steps

As demonstrated by Liu et al. (paper), selective inhibition of P2Y11 with NF 340 unlocks a new layer of mechanistic insight into cancer cell migration and immune regulation. Future research will likely focus on expanding the repertoire of P2Y11-driven models, refining combinatorial protocols with other pathway inhibitors, and leveraging high-content readouts for drug discovery. The specificity and reproducibility of NF 340, when paired with robust workflow design, position it as a cornerstone reagent for next-generation immunology and oncology research.